[Thalidomide: new therapeutic indications?].
Nau
Jean-Yves
JY
jeanyves.nau@gmail.com
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome; D054079:Vascular Malformations / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D007917:Leprostatic Agents; D013792:Thalidomide